摘要
准确快速的病原菌诊断,同时报告正确的药敏结果,是实现感染性疾患个体化治疗的前提.美国临床和实验室标准协会（CLSI）每年修订的折点引起临床工作者的广泛关注.本文介绍了CLSI M100-S24的更新内容.CLSI 2014年文件最大改变之处是修改了肠杆菌科细菌头孢吡肟的药敏折点,并引入“剂量依赖性敏感”的概念.正确理解和运用新折点,对优化药物使用具有重要意义.
Individualized therapy is dependent on rapid and accurate diagnosis of pathogens,and refined susceptibility reporting.The annually revised interpretive criteria of Clinical and Laboratory Standards Institute （CLSI） causes widespread concern of microbiologists.The major changes in CLSI M100-S24 are described in this article.The document mainly changed the Cefepime breakpoint for Enterobacteriaceae and introduced a new concept--＆quot; susceptible-dose dependent＆quot; interpretive category.Optimizing the use of antimicrobial agents requires clinical microbiologists and clinicians to have a good knowledge of the new breakpoints.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2014年第4期256-260,共5页
Chinese Journal of Laboratory Medicine
关键词
抗菌药
微生物敏感性试验
肠杆菌科
Anti-bacterial agents
Microbial sensitivity tests
Enterobacteriaceae
